OCU400 Second Eye Dosing for retinitis pigmentosa

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 24 Jan 2022: Trial registered, NCT05203939
  2. 24 Jan 2022: Trial started, NCT05203939

The trials

NCT05203939: Study to Assess the Safety and Efficacy of OCU400 for Retinitis Pigmentosa and Leber Congenital Amaurosis

State
Under way
Phase
Phase 1 and Phase 2
People
22 taking part
Started
24 Jan 2022
Primary completion
Mar 2027
Arms
Second Eye Dosing
Results
None posted
  1. 24 Jan 2022: Trial registered
  2. 24 Jan 2022: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.